Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XG2002
- Development stage
- Phase 1
- Lead developer
- Xgene Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
XG2002 is an orally bioavailable small molecule modulator of the Transient Receptor Potential Melastatin 8 (TRPM8) channel, developed by Xgene Pharmaceutical Group. TRPM8 is a cold-sensing non-selective cation channel primarily expressed in sensory neurons and is a key mediator in the detection of environmental cold and the development of cold allodynia. XG2002 is designed to target TRPM8 to treat various chronic pain conditions, with a specific focus on metastatic bone pain. The drug candidate has successfully completed a Phase 1 clinical trial in Australia, which assessed its safety, tolerability, and pharmacokinetics in healthy subjects.
02
Targets
TRPM8 (Transient receptor potential cation channel subfamily M member 8)
Beyond the preview
Go deeper on XG2002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XG2002.